• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型抗CD44变体7/8单克隆抗体CMab-34的研发,用于多种口腔癌治疗应用

Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, CMab-34, for Multiple Applications against Oral Carcinomas.

作者信息

Suzuki Hiroyuki, Ozawa Kazuki, Tanaka Tomohiro, Kaneko Mika K, Kato Yukinari

机构信息

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.

出版信息

Biomedicines. 2023 Apr 5;11(4):1099. doi: 10.3390/biomedicines11041099.

DOI:10.3390/biomedicines11041099
PMID:37189717
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10136282/
Abstract

Cluster of differentiation 44 (CD44) has been investigated as a cancer stem cell (CSC) marker as it plays critical roles in tumor malignant progression. The splicing variants are overexpressed in many carcinomas, especially squamous cell carcinomas, and play critical roles in the promotion of tumor metastasis, the acquisition of CSC properties, and resistance to treatments. Therefore, each CD44 variant (CD44v) function and distribution in carcinomas should be clarified for the establishment of novel tumor diagnosis and therapy. In this study, we immunized mouse with a CD44 variant (CD44v3-10) ectodomain and established various anti-CD44 monoclonal antibodies (mAbs). One of the established clones (CMab-34; IgG, kappa) recognized a peptide that covers both variant 7- and variant 8-encoded regions, indicating that CMab-34 is a specific mAb for CD44v7/8. Moreover, CMab-34 reacted with CD44v3-10-overexpressed Chinese hamster ovary-K1 (CHO) cells or the oral squamous cell carcinoma (OSCC) cell line (HSC-3) by flow cytometry. The apparent of CMab-34 for CHO/CD44v3-10 and HSC-3 was 1.4 × 10 and 3.2 × 10 M, respectively. CMab-34 could detect CD44v3-10 in Western blotting and stained the formalin-fixed paraffin-embedded OSCC in immunohistochemistry. These results indicate that CMab-34 is useful for detecting CD44v7/8 in various applications and is expected to be useful in the application of OSCC diagnosis and therapy.

摘要

分化簇44(CD44)已被作为一种癌症干细胞(CSC)标志物进行研究,因为它在肿瘤恶性进展中起关键作用。剪接变体在许多癌症中过度表达,尤其是在鳞状细胞癌中,并且在促进肿瘤转移、获得CSC特性以及抵抗治疗方面发挥关键作用。因此,为了建立新的肿瘤诊断和治疗方法,应阐明每种CD44变体(CD44v)在癌症中的功能和分布。在本研究中,我们用CD44变体(CD44v3 - 10)胞外域免疫小鼠,并建立了多种抗CD44单克隆抗体(mAb)。其中一个建立的克隆(CMab - 34;IgG,κ)识别一个覆盖变体7和变体8编码区域的肽段,表明CMab - 34是CD44v7/8的特异性单克隆抗体。此外,通过流式细胞术,CMab - 34与过表达CD44v3 - 10的中国仓鼠卵巢-K1(CHO)细胞或口腔鳞状细胞癌(OSCC)细胞系(HSC - 3)发生反应。CMab - 34对CHO/CD44v3 - 10和HSC - 3的表观解离常数分别为1.4×10和3.2×10 M。CMab - 34在蛋白质印迹中可检测到CD44v3 - 10,并且在免疫组织化学中可对福尔马林固定石蜡包埋的OSCC进行染色。这些结果表明,CMab - 34在各种应用中可用于检测CD44v7/8,有望在OSCC诊断和治疗应用中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/23e1ccfbda92/biomedicines-11-01099-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/18db2e07a24f/biomedicines-11-01099-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/68ad62ec5440/biomedicines-11-01099-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/135f16e900e5/biomedicines-11-01099-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/35acf0cfead1/biomedicines-11-01099-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/23e1ccfbda92/biomedicines-11-01099-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/18db2e07a24f/biomedicines-11-01099-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/68ad62ec5440/biomedicines-11-01099-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/135f16e900e5/biomedicines-11-01099-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/35acf0cfead1/biomedicines-11-01099-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/debc/10136282/23e1ccfbda92/biomedicines-11-01099-g005.jpg

相似文献

1
Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody, CMab-34, for Multiple Applications against Oral Carcinomas.一种新型抗CD44变体7/8单克隆抗体CMab-34的研发,用于多种口腔癌治疗应用
Biomedicines. 2023 Apr 5;11(4):1099. doi: 10.3390/biomedicines11041099.
2
Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody CMab-3 for Multiple Applications against Pancreatic Carcinomas.新型抗CD44变体5单克隆抗体CMab-3的研发及其在多种胰腺癌治疗中的应用
Antibodies (Basel). 2023 Apr 28;12(2):31. doi: 10.3390/antib12020031.
3
Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody CMab-108 for Immunohistochemistry.用于免疫组织化学的新型抗CD44变体4单克隆抗体CMab-108的研发
Curr Issues Mol Biol. 2023 Feb 25;45(3):1875-1888. doi: 10.3390/cimb45030121.
4
A Novel Anti-CD44 Variant 3 Monoclonal Antibody CMab-6 Was Established for Multiple Applications.一种新型抗 CD44 变体 3 单克隆抗体 CMab-6 的建立及其在多种应用中的研究。
Int J Mol Sci. 2023 May 7;24(9):8411. doi: 10.3390/ijms24098411.
5
Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody CMab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas.一种用于口腔鳞状细胞癌免疫组织化学分析的新型抗CD44变体10单克隆抗体CMab-18的建立。
Curr Issues Mol Biol. 2023 Jun 21;45(7):5248-5262. doi: 10.3390/cimb45070333.
6
Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody CMab-9 for Multiple Applications against Colorectal Carcinomas.开发一种新型抗 CD44 变体 6 单克隆抗体 CMab-9,用于多种结直肠癌的治疗。
Int J Mol Sci. 2023 Feb 16;24(4):4007. doi: 10.3390/ijms24044007.
7
Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody CMab-94 against Gastric Carcinomas.一种新型抗CD44变异体8单克隆抗体CMab-94针对胃癌的研发。
Antibodies (Basel). 2023 Jul 4;12(3):45. doi: 10.3390/antib12030045.
8
A Novel Anti-CD44 Variant 9 Monoclonal Antibody CMab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers.一种新型抗CD44变体9单克隆抗体CMab-1被开发用于结直肠癌的免疫组织化学分析。
Curr Issues Mol Biol. 2023 Apr 20;45(4):3658-3673. doi: 10.3390/cimb45040238.
9
Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.开发一种新型抗 CD44 单克隆抗体,用于多种治疗食管鳞癌的应用。
Int J Mol Sci. 2022 May 16;23(10):5535. doi: 10.3390/ijms23105535.
10
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.抗 CD44 变体 10 单克隆抗体在口腔鳞状细胞癌小鼠异种移植模型中发挥抗肿瘤活性。
Int J Mol Sci. 2024 Aug 24;25(17):9190. doi: 10.3390/ijms25179190.

引用本文的文献

1
Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.抗 CD44 变体 10 单克隆抗体在口腔鳞状细胞癌小鼠异种移植模型中发挥抗肿瘤活性。
Int J Mol Sci. 2024 Aug 24;25(17):9190. doi: 10.3390/ijms25179190.
2
Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer.抗 CD44 单克隆抗体在食管癌异种移植模型中的抗肿瘤活性。
Oncol Rep. 2024 Nov;52(5). doi: 10.3892/or.2024.8806. Epub 2024 Sep 2.
3
Editorial of Special Issue "Oral Cancer: From Pathophysiology to Novel Therapeutic Approaches".

本文引用的文献

1
Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.去岩藻糖基化抗 EpCAM 单克隆抗体在结直肠癌异种移植模型中的抗肿瘤活性。
Int J Mol Med. 2023 Feb;51(2). doi: 10.3892/ijmm.2023.5221. Epub 2023 Jan 20.
2
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
3
A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG-f) Exerts Antitumor Activity in Xenograft Model.一种去岩藻糖基化的抗EpCAM单克隆抗体(EpMab-37-mG-f)在异种移植模型中发挥抗肿瘤活性。
《“口腔癌:从病理生理学到新型治疗方法”特刊社论》
Biomedicines. 2023 Oct 11;11(10):2748. doi: 10.3390/biomedicines11102748.
4
Establishment of a Novel Anti-CD44 Variant 10 Monoclonal Antibody CMab-18 for Immunohistochemical Analysis against Oral Squamous Cell Carcinomas.一种用于口腔鳞状细胞癌免疫组织化学分析的新型抗CD44变体10单克隆抗体CMab-18的建立。
Curr Issues Mol Biol. 2023 Jun 21;45(7):5248-5262. doi: 10.3390/cimb45070333.
5
Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody CMab-94 against Gastric Carcinomas.一种新型抗CD44变异体8单克隆抗体CMab-94针对胃癌的研发。
Antibodies (Basel). 2023 Jul 4;12(3):45. doi: 10.3390/antib12030045.
6
A Novel Anti-CD44 Variant 9 Monoclonal Antibody CMab-1 Was Developed for Immunohistochemical Analyses against Colorectal Cancers.一种新型抗CD44变体9单克隆抗体CMab-1被开发用于结直肠癌的免疫组织化学分析。
Curr Issues Mol Biol. 2023 Apr 20;45(4):3658-3673. doi: 10.3390/cimb45040238.
7
A Novel Anti-CD44 Variant 3 Monoclonal Antibody CMab-6 Was Established for Multiple Applications.一种新型抗 CD44 变体 3 单克隆抗体 CMab-6 的建立及其在多种应用中的研究。
Int J Mol Sci. 2023 May 7;24(9):8411. doi: 10.3390/ijms24098411.
Antibodies (Basel). 2022 Nov 24;11(4):74. doi: 10.3390/antib11040074.
4
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer.人乳头瘤病毒相关性口咽癌治疗减量化的共识、争议与未来方向。
CA Cancer J Clin. 2023 Mar;73(2):164-197. doi: 10.3322/caac.21758. Epub 2022 Oct 28.
5
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma.癌症特异性抗血小板蛋白CAR-T细胞与溶瘤性单纯疱疹病毒G47Δ联合治疗胶质母细胞瘤的疗效
Mol Ther Oncolytics. 2022 Jul 20;26:265-274. doi: 10.1016/j.omto.2022.07.006. eCollection 2022 Sep 15.
6
Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in an animal model.嵌合抗原受体修饰的人细胞毒性 T 细胞增强了抗 Podoplanin 人源化抗体的抗实体瘤反应:动物模型研究。
Genes Cells. 2022 Sep;27(9):549-558. doi: 10.1111/gtc.12972. Epub 2022 Jul 17.
7
Development of a Novel Anti-CD44 Monoclonal Antibody for Multiple Applications against Esophageal Squamous Cell Carcinomas.开发一种新型抗 CD44 单克隆抗体,用于多种治疗食管鳞癌的应用。
Int J Mol Sci. 2022 May 16;23(10):5535. doi: 10.3390/ijms23105535.
8
A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers.去岩藻糖基化的鼠抗 CD10 单克隆抗体(31-mG-f)在肾细胞癌的小鼠异种移植模型中发挥抗肿瘤活性。
Monoclon Antib Immunodiagn Immunother. 2022 Dec;41(6):320-327. doi: 10.1089/mab.2021.0049. Epub 2022 Apr 27.
9
A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG-f) Exerts Antitumor Activity in a Mouse Xenograft Model of CD10-Overexpressed Tumors.去岩藻糖基化鼠抗 CD10 单克隆抗体(31-mG-f)在 CD10 过表达肿瘤的小鼠异种移植模型中发挥抗肿瘤活性。
Monoclon Antib Immunodiagn Immunother. 2022 Apr;41(2):59-66. doi: 10.1089/mab.2021.0048.
10
Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody (134-mG-f) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma.去岩藻糖基化抗表皮生长因子受体单克隆抗体(134-mG-f)在犬骨肉瘤的小鼠异种移植模型中发挥抗肿瘤活性。
Monoclon Antib Immunodiagn Immunother. 2022 Feb;41(1):1-7. doi: 10.1089/mab.2021.0036.